Florence Spitler, DO
Family Medicine · Georgetown, TXNPI 1952381071
Payments from drug & device makers
Across 366 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$856
- AbbVie$548
- Amgen$483
- Amarin Pharma, Inc.$480
- AstraZeneca$445
- Merck$361
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,49099%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $856 |
| AbbVie(2 entities) | 44 | $548 |
| Amgen(2 entities) | 30 | $483 |
| Amarin Pharma, Inc. | 30 | $480 |
| AstraZeneca | 21 | $445 |
| Merck | 27 | $361 |
| Boehringer Ingelheim | 22 | $292 |
| GSK | 24 | $277 |
| Esperion Therapeutics, Inc. | 9 | $254 |
| Astellas Pharma US Inc | 9 | $233 |
| Lilly USA, LLC | 23 | $223 |
| Abbott | 7 | $141 |
| Biohaven Pharmaceuticals, Inc. | 5 | $98 |
| Johnson & Johnson | 7 | $85 |
| Genentech USA, Inc. | 4 | $74 |
| Arbor Pharmaceuticals, Inc. | 5 | $73 |
| Novartis | 4 | $72 |
| Pfizer | 4 | $63 |
| Mylan Specialty L.p. | 3 | $61 |
| IBSA Pharma Inc. | 3 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Medtronic(2 entities) | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Stryker | 1 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Shire North American Group Inc | 2 | $29 |
| Clarus Therapeutics Inc. | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Cranial Technologies, Inc | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Gilead | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,565 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 64 | $68,832 |
| MounjaroTirzepatide | 46 | $55,300 |
| EliquisApixaban | 27 | $44,630 |
| ProliaDenosumab | 26 | $44,047 |
| OzempicSemaglutide | 29 | $38,872 |
| XareltoRivaroxaban | 25 | $38,217 |
| TrulicityDulaglutide | 12 | $19,385 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $14,737 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $10,520 |
| Levothyroxine Sodium | 721 | $8,114 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $7,698 |
| Estradiol | 67 | $7,481 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $7,354 |
| Atorvastatin Calcium | 753 | $5,654 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $5,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $223 | $74,68558 claims |
| MerckJanuvia, Dulera | $361 | $74,28476 claims |
| PfizerEliquis | $63 | $44,63027 claims |
| AmgenProlia | $483 | $44,04726 claims |
| Novo NordiskOzempic | $856 | $38,87229 claims |
| Johnson & JohnsonXarelto | $85 | $38,21725 claims |
| AstraZenecaSymbicort, Bevespi Aerosphere | $445 | $17,87428 claims |
| GSKTrelegy Ellipta | $277 | $14,73714 claims |
| AbbVieSynthroid | $548 | $5,29993 claims |
| Astellas Pharma US IncVesicare | $233 | $4,45311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Georgetown
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.